The Vanguard Group Discloses Position in Life Science REIT plc

On May 16, 2025, The Vanguard Group, Inc. filed a Form 8.3 disclosure regarding its stake in Life Science REIT plc. This document is a requirement under Rule 8.3 of the Takeover Code, mandating transparency from entities with significant interests in relevant securities. Vanguard’s interest in Life Science REIT amounts to 3,467,962 ordinary shares, which equates to 0.99% of the total shares.

In recent activities, Vanguard sold 43,239 shares at a price of 0.43 GBP per share. The disclosure further clarified that there were no derivative transactions or additional rights associated with these securities. There are also no indemnity arrangements or agreements influencing dealings or voting rights. No supplemental forms were attached to the disclosure, indicating a straightforward position with no additional complexities.